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Application of a Systems Pharmacology-Based Placebo
Population Model to Analyze Long-Term Data of
Postmenopausal Osteoporosis
J Berkhout1,2, JA Stone3, KM Verhamme1, BH Stricker4,5, MC Sturkenboom1, M Danhof2 and TM Post6
Osteoporosis is a progressive bone disease characterized by decreased bone mass resulting in increased fracture risk. The
objective of this investigation was to test whether a recently developed disease systems analysis model for osteoporosis
could describe disease progression in a placebo-treated population from the Early Postmenopausal Intervention Cohort
(EPIC) study. First, we qualified the model using a subset from the placebo arm of the EPIC study of 222 women who had
similar demographic characteristics as the 149 women from the placebo arm of the original population. Second, we applied
the model to all 470 women. Bone mineral density (BMD) dynamics were changed to an indirect response model to describe
lumbar spine and total hip BMD in this second population. This updated disease systems analysis placebo model describes
the dynamics of all biomarkers in the corresponding datasets to a very good approximation; a good description of an
individual placebo response will be valuable for evaluating treatments for osteoporosis.
CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 516–526; doi:10.1002/psp4.12006; published online on 22 August 2015.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  A complete mechanism-based model describing osteo-
blast and osteoclast activity has been reduced in order to apply it in a population approach. It was shown that the model
reduction did not jeopardize the dynamical properties of the model. The reduced model was successfully applied to
describe responses in treatment with various doses of tibolone and/or calcium in postmenopausal women. • WHAT
QUESTIONS DID THIS STUDY ADDRESS?  Can the current disease systems analysis model be used to describe the
disease progression in another external placebo-treated population? • WHAT THIS STUDY ADDS TO OUR KNOWL-
EDGE  The developed placebo model could describe the data of this new population to a very good approximation,
showing the strength of a population systems pharmacology approach. • HOW THIS MIGHT CHANGE CLINICAL PHAR-
MACOLOGY AND THERAPEUTICS  The effect of a drug involves understanding of the progression of the disease
and the effect of placebo. The developed model will therefore allow for a better understanding of disease progression of
osteoporosis in treated and untreated patients.
Osteoporosis is defined as a progressive systematic skele-
tal disorder that is characterized by the loss of bone tissue,
disruption of bone architecture, and bone fragility that leads
to an increased risk of fractures.1 Removal and formation
of bone occurs in a continuous remodeling cycle, which is a
carefully regulated process involving many local and sys-
temic factors.2 Both men and women lose bone mass when
they age. However, in postmenopausal women, mainly due
to the decline in estrogen levels during menopausal transi-
tion: 1) the activity of osteoclasts (cells responsible for
resorbing mineralized bone) increases compared to the
activity of osteoblasts (cells responsible for synthesis of
new bone matrix); 2) osteoblast activity also increases, but
with a delay. The combination of the two processes result
in higher bone turnover. The rapid (menopause) and slow
(aging) components of disease progression underlie ele-
vated fracture rates in vertebrae and hip joints, increased
mortality, and significant healthcare costs.3,4 Various treat-
ments exist that aim to either promote bone formation or
inhibit bone resorption, yet postmenopausal osteoporosis
still represents an ongoing clinical challenge with decreases
in quality of life and increase in healthcare costs. Addition-
ally, given the rapidly aging population (both men and
women) the burden of this disease is expected to increase.
Disease systems analysis models are used to study
treatment effects on disease progression within the context
of interacting networks.5 By doing so, these models allow
for the comparison of effectiveness and safety of different
treatment options. In order to estimate the actual treatment
effect it is essential to account for the time course of the
drug and/or placebo effects and disease progression.5,6
Although it is sometimes difficult to differentiate the placebo
response and the underlying disease progression, this
distinction is important for designing clinical trials and
interpreting results. Furthermore, one of the premises of
mechanism-based disease systems analysis models is that
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the model structure and the values of the system-specific
parameters would ultimately be independent of the type of
treatment. Therefore, in principle, they provide the opportu-
nity to predict disease progression in another comparable
population than the population that was used for model
development and parameter fitting. In this study we will use
the term “disease progression” for disease progression of
the placebo arm of the Early Postmenopausal Intervention
Cohort (EPIC) study in which all subjects took (at least)
500 mg calcium per day.
The objective of this study was to test whether a current
disease systems analysis model for postmenopausal osteo-
porosis can adequately describe disease progression in a
placebo-treated population of postmenopausal women. To
this end, we focused on the contribution of the postmeno-
pausal transition in combination with the placebo effect
(i.e., calcium effect) on the osteoblast and osteoclast activ-
ity. For the current model, the placebo effect captures the
response to daily calcium intake and the underlying disease
progression. Variation in placebo response within and
among clinical trials can substantially affect conclusions
about the efficacy of new medications. Developing a robust
population model to describe the placebo arm is of interest
to enable quantification of drug effects, and eventually to
guide the design of clinical trials for osteoporosis treatment.
This outcome of the placebo arm is the result of individual
placebo response (including the eventual effect of calcium
intake) and progression of the disease.
For osteoporosis, different models have been proposed.
The group of Peterson and Riggs have published a
physiology-based mathematical representation of integrated
calcium homeostasis and bone remodeling,7 which they
later extended to show nonlinear changes in lumbar spine
(LS) bone mineral density (BMD) upon denosumab treat-
ment, a monoclonal antibody that decreases bone resorp-
tion,8 and to describe the impact of progressive loss of
kidney function.9 This group has also described estrogen-
related changes in bone and calcium balance through men-
opause transition10,11 with an extension to fracture risks.12
In their current form these extensive physiology-based
models are challenging to apply in a population approach,
which captures the existing variability in addition to the
structural dynamics. In order to do so, Danhof and col-
leagues have shown that a full mechanism-based model of
interacting osteoblast and osteoclasts can be reduced to a
simpler model, which can describe the dynamics of the full
model13 to a very good approximation (for details on the
simplification, see Ref. 14). The reduced model was then
applied to clinical data from postmenopausal women receiv-
ing calcium and tibolone.15 This reduced systems disease
model ensures parameter identifiability and could describe
the dynamics of biomarkers that respond at widely different
timescales to drug treatment. Even though the Peterson
and Riggs model describes cellular through organ level
aspects involved in bone and calcium homeostasis, it also
contains a high number of differential equations and param-
eters to be estimated. Due to this model complexity, we will
here focus on the disease systems analysis model devel-
oped by Post et al.15
In this study, we applied an osteoporosis disease sys-
tems analysis model15 to the placebo arm of a clinical study
from the EPIC study.16 It should be noted that the EPIC
study was intended as an osteoporosis prevention study.17
As such, patients enrolled were thought to be at risk of
osteoporotic bone loss, but they did not meet the usual cri-
teria for low bone BMD that would define osteoporosis (see
Methods). The range of “years since menopause” (YSM) in
the EPIC study population (0.5–27 years) is larger than in
the population of the tibolone study (1–4 years). A charac-
teristic of the disease systems analysis model is that the
timescale of the disease process is incorporated rather
than the timescale relative to the start of the study. There-
fore, this systems pharmacology approach allowed us to 1)
qualify the disease systems analysis model using an exter-
nal dataset; 2) develop a robust placebo model; 3) chal-
lenge the model with data over a longer time after the
onset of the disease (e.g., the start of the menopause); 4)
relate various timescales (short- and long-term biomarkers);
and 5) directly address and describe the covariate YSM
instead of it being a covariate at baseline. The latter was
possible because YSM and not study time was used as the
timescale in the model.
METHODS
Subject population and study design
Data for the current analysis were obtained from the EPIC
study, a clinical trial of oral alendronate in 1,609 postmeno-
pausal women who were randomly assigned in a double-
blind manner to receive alendronate, placebo, or open-label
estrogen-progestin in order to evaluate the potential to pre-
vent osteoporosis. In this study we only used data from the
placebo arm (n5470). Briefly, all participants were
between 45 and 59 year of age and at least 6 months past
menopause at baseline, were in good general health, and
had no clinical or laboratory evidence of confounding sys-
temic disease.1 Four study centers (two in the United
States and two in Europe) were involved in this trial. To
ensure that most women who entered the study did not yet
have osteoporosis, only 10% of the women enrolled at
each center were allowed to have an LS-BMD below 0.8 g/
cm2, as measured by dual-energy x-ray absorptiometry. All
women adhered to therapy (had taken at least 80% of the
prescribed number of tablets, confirmed by tablet count).
Dietary calcium intake was estimated at baseline and annu-
ally during the study on the basis of a food-frequency
questionnaire.
Measurement of BMD and biochemical markers of
bone turnover
BMD of LS and total hip (TH, defined as the femoral neck
plus trochanter and intertrochanteric area) was measured
by dual-energy x-ray absorptiometry (model 2000, Hologic,
Waltham, MA) twice at baseline and annually thereafter.
BMD is reported in g/cm2. Blood and morning second-void
urine samples were collected after an overnight fast at
baseline and every 6 months thereafter. Bone resorption
was estimated by using urine N-telopeptide cross-links
of type I collagen (NTX) (Osteomark, Ostex, Seattle, WA).
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NTX is reported as nmol bone collagen equivalents (bce)
and corrected for creatinine excretion (nmol bce/mmol cr).
In addition, the serum level of bone-specific alkaline phos-
phatase (BSAP) was measured at baseline and at months
6, 12, 24, 36, 42, and 48 in a random sample of 205
women to estimate bone formation (Ostase, Hybritech, San
Diego, CA). BSAP is reported in ng/mL.
Mechanism-based disease systems analysis model
In an earlier publication it was demonstrated that the com-
pletely mechanistic bone cell interaction model proposed by
Lemaire et al.,13 which involves responding but not yet
active osteoblasts (R), active osteoblasts (B), and active
osteoclasts (C), can be mathematically reduced while main-
taining its dynamic properties.14 The reduced model is
shown in Figure 1 and only involves active B and C, which
is given by the following system of equations:
dy
dt
¼ kB r zð Þ2yf g
dz
dt
¼ 1
11zs
2
11f tð Þr2 zð Þ y  PCa2r zð Þz
 
r zð Þ ¼ 11zsð Þ z
z1zs
; zs ¼ C
s
C0
8>>>>><
>>>>>>:
(1)
where y and z are defined as y=B/B0 and z=C/C0 or, in
other words: the activity of the osteoblast (B) and osteo-
clast (C) relative to their baseline values, B0 and C0,
respectively. kB is the apoptosis rate of active osteoblasts.
Cs is the value of C for which approximately half of the
transforming growth factor-b (TGF-b) receptors are occu-
pied.13 The function f(t) models disease progression. We
used the function as proposed by Post et al.:15
f tð Þ ¼ e2kestrogen t (2)
where kestrogen is the first-order rate constant of disease
progression. In Eq. 1 PCa is the placebo effect that starts at
tstart and the effect of placebo is assumed to wear off over
time with rate constant kCa:
PCa tð Þ ¼
1 0 < t < tstart
12Pmax 12e2kCa t2tstartð Þ
   e2kCa t2tstartð Þ t > tstart
(
(3)
where Pmax is a measure for the calcium-induced inhibition
of the RANK- RANKL-OPG through parathyroid hormone
(PTH),7,13,18 which we take to be unity (100%).
The mechanistic core model (Eq. 1) is linked to the corre-
sponding biomarkers (Figure 1) using the following trans-
ducer functions:
NTX ¼ NTX0  zqNTX
BSAP ¼ BSAP0  yqBSAP
(4)
These transducer functions involve 1) a baseline parame-
ter (NTX0, BSAP0), which links the relative cell activity to
the baseline value of the marker, and 2) a positive trans-
duction parameter (q), which links relative changes in cell
activity to those in the corresponding bone turnover
markers.
In comparison to the biomarkers NTX and BSAP,
changes in LS-BMD and TH-BMD are relatively slow and
have dynamics and timescales of their own, which were
described by the zeroth-order process (15):
dLS2BMD
dt
¼ kLS  12SqBMDð Þ
dTH2BMD
dt
¼ kTH  12SqBMDð Þ
; S ¼ z
y
(5)
At baseline (healthy bone status), y51 and z5 1 and
hence S51. In light of Eq. 5 this means that if y and z
stay at baseline, then LS-BMD and TH-BMD do not change
with time. However, if either or both y and z change the
overall change in BMD depends on S.
Body composition is known to induce changes in bone
morphology.19 Body mass index (BMI) was incorporated
as a fraction of the baseline of LS-BMD (LS-BMD0) and
baseline TH-BMD (TH-BMD0) using the median BMI of
25.2 kg/m2.
In order to initialize the model at a healthy normal state
(z, y, and S51), individual timescales were normalized
using time-since-onset-of-menopause as the characteristic
time frame (Figure 2). Due to this normalization, individual
subject’s disease trajectories are harmonized to an identical
start point and allowed to set the onset of menopause for
the entire population at t5 0. When combining the individ-
ual disease trajectories in a population approach, the over-
all population’s disease trajectory can then be defined and
the need for a disease status covariate on baseline is not
required as its influence on the variability is already
described.
Data analysis
Description of the data analysis, including the model file,
can be found in the Supplementary Information.
RESULTS
Comparison of baseline demographic characteristics
Before applying the model, the baseline demographic char-
acteristics for the placebo arms of the tibolone (originator)
and EPIC studies were compared (Table 1). Data from the
EPIC study were split into two different datasets: EPIC 1,
which only includes women with YSM between 1 and 5 years
(n5 222), and EPIC 2, which contains the entire range of
YSM (n5 470). EPIC 1 was created to have demographic
characteristics as close as possible to the tibolone study and
was used for qualification of the disease systems analysis
model. EPIC 2 was used to challenge the model for a longer
time after the onset of the menopause. This led to mean
YSM for EPIC 1 and EPIC 2 that were, respectively, compa-
rable and higher when compared to the tibolone study. Fur-
thermore, mean age was somewhat lower in EPIC 1 but
similar for EPIC 2 in comparison to the tibolone study. There
was no meaningful difference between the two clinical stud-
ies in terms of BMI. Additionally, for EPIC 1 and EPIC 2 we
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Figure 2 Normalization of individual timescales based on years since menopause (YSM). (a) Typical imaginary disease progression
curve for osteoporosis (black solid line). Disease progression is plotted as relative fraction of healthy status (51) vs. years since meno-
pause. Five subjects (no real data) are shown that have different YSM at the start of the study. For these subjects we assume that
they complete the study duration of 4 years as indicated by the colored lines. At the start of the study, these five subjects are thus at
different locations on the disease progression curve. The shaded gray area represents the exclusion criteria for YSM. The range of
YSM for EPIC 1 (1YSM5) and for EPIC 2 (all YSM) is indicated by the black arrows. (b) Normalization based on study time for the
five subjects (same colors as in a). This normalization harmonizes the individual subjects disease trajectory to an identical study start-
ing point.
Figure 1 Schematic representation of the mechanism-based disease systems analysis model. Active osteoblast and osteoclast cells
and the indicated interactions form the mechanism-based core (shown in gray) of this model, which are linked to the biomarkers, NTX,
BSAP, LS-BMD, and TH-BMD as shown in the dotted area. PTH stands for parathyroid hormone, TGF-b for transforming growth
factor-b, OPG for osteoprotegerin, RANK for receptor activator of NF-jB, and RANKL for receptor activator of NF-jB ligand. RANKL
binds to RANK and promotes osteoclast differentiation, while OPG inhibits this differentiation by binding RANKL. Figure and legend
were adapted from Ref. 15.
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observed a lower mean value for LS-BMD and TH-BMD. The
biomarker for resorption, NTX, was higher in the two EPIC
studies than in the tibolone study. NTX, a specific collagen
degradation product, is produced by osteoclastic bone
resorption. When bone resorption is accelerated, which is
known to happen in response to estrogen deficiency,20 NTX
levels in urine increase as well. BSAP, on the other hand, was
measured using two different assays and is reported in differ-
ent units. To account for these different units a scaling
parameter was introduced (assuming a linear relation
between U/L and ng/mL, see below).
Qualification of the disease systems analysis model
using EPIC 1
Previous studies have indicated that most women have a
rapid phase of bone loss following menopause, followed by
a protracted period of slower bone loss (age-related) that
continues into old age.18,19 The model takes the timescale
of the disease process into account (i.e., YSM, see Meth-
ods and Figure 2).
Due to the design of the tibolone study (see Supplemen-
tary Information), only the effect on disease progression
between years 1 and 4 after menopause could be ana-
lyzed. Therefore, to qualify the disease systems analysis
model we first analyzed the results using data from EPIC 1
(Table 1). In order to apply the model (see Methods) to
this dataset two modifications were applied: first, a scaling
parameter was introduced to account for the different units
for BSAP in the two clinical studies. The baseline value for
BSAP was fixed at the value found in the tibolone study (in
units U/L) and we only estimated the value of the scaling
parameter. This scaling parameter (kBSAP,0) affects the
baseline value of BSAP:
BSAP ¼ BSAP0  11kBSAP;0
   yqBSAP (6)
Second, the placebo effect during treatment with calcium
was implemented using a separate calcium elimination rate
constant (kCa) for the onset and offset of the placebo
function:
PCa tð Þ ¼
1 for 0 < t < tstart
12Pmax 12e2kCa;onset t2tstartð Þ
   e2kCa;offset t2tstartð Þ fort > tstart
(
(7)
This adaptation in placebo function allows for a pla-
cebo effect that wears off over time much more slowly
than the original model, something we also observed dur-
ing data analysis of the placebo response for the EPIC
study.
Since it was our aim to qualify the model, we fixed the
system-specific parameters and estimated the parameters
related to the placebo function, transducer functions for
bone turnover markers, and BMD as well as the interindi-
vidual (IIV) and residual variability observed for the bone
turnover markers and BMD (see Table 2). All parameter
values were in accordance with the original values or with
the available data and could be estimated with good preci-
sion. Goodness of fit plots indicated that there were no
underlying trends of model misspecifications. Overall, we
found that the disease systems analysis model was able to
satisfactorily predict the course of the changes for all four
measurements in this external dataset.
Application of disease systems analysis model to all
data in the placebo arm of the EPIC study
The change in LS-BMD and TH-BMD is described by a
zeroth-order process (Eq. 5), which can be viewed as a
simplification of classical turnover models in which the loss
term is omitted. For EPIC 1 (and the original tibolone study)
this zeroth-order process turned out to be a good approxi-
mation. However, when analyzing all 470 women in the pla-
cebo arm of EPIC 2 a large deviation between model
predictions and observed values was found for LS-BMD
and TH-BMD, but not for the resorption (NTX) and forma-
tion (BSAP) markers. Likely this is due to the fact that a
longer disease trajectory is being looked at. Therefore, we
used an indirect response model for the BMD dynamics
proposed by others.8,23 Changes in BMD are described
with osteoblasts and osteoclasts stimulating the production
and degradation processes as:
Table 1 Comparison of demographic characteristics of the placebo arms from the tibolone and EPIC study. The EPIC study was split up in two groups (EPIC
1 and EPIC 2) based on the years since menopause (YSM)
Placebo arm of EPIC study
Characteristic Placebo arm of tibolone study EPIC 1 1<YSM<5 EPIC 2 All YSM
Subjects, n 149 222 470
Mean age at baseline6SD, years 53.063.3 50.36 3.3a 53.363.7c
Mean BMI at baseline6SD, kg/m2 25.363.8 25.26 3.5a 25.263.6a
Mean time since menopause at baseline6SD, years 2.360.9 2.56 1.4c 5.765.4b
Mean LS-BMD at baseline6SD, g/cm2 1.0460.16 0.936 0.12b 0.9460.12b
Mean TH-BMD at baseline6SD, g/cm2 0.8960.13 0.846 0.11d 0.8560.12d
Mean BSAP at baseline6SD (U/Le and ng/mlf) 106.7629.6 11.26 4.4b 11.164.4b
Mean NTX at baseline6SD, nmol bce/mmol cr 50.1623.0 67.16 38.1b 88.0645.0b
aNot significant when either of the two EPIC datasets is compared to tibolone study, using two-sample Student’s t-test assuming equal variance.
bP< 0.001 when either of the two EPIC datasets is compared to tibolone study using Welch’s t-test.
cP< 0.05 when compared to tibolone study using Welch’s t-test.
dP< 0.001 when either of the two EPIC datasets is compared to tibolone study using two-sample Student’s t-test assuming equal variance.
eDetermination of BSAP activity was based on selective inhibition of the three common isoenzymes of alkaline phosphatase (bone, liver, and a third group of
isoenzymes from intestinal mucosa, placenta, and neoplastic tissue that are sensitive to l-phenylalanine) and reported in U/L.22
fDetermination of BSAP activity was based on a solid phase, monoclonal antibody immunoenzymetric assay and is reported in ng/mL.16
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Table 2 Comparison of the population parameter estimates for the placebo arm of the tibolone model and the models applied to of EPIC 1 and EPIC 2
Parameter (unit) Description
Value (%CV)
tibolone study
Value (%CV)
EPIC 1 1£YSM£5
Value
(%CV) EPIC
2 All YSM
System-related parameters
zs (fraction) Constant in r(z) fixed at 0.659
kB (day
21) Elimination rate constant
of osteoblast
fixed at 0.0109
kestrogen (day
21) Estrogen elimination rate constant fixed at 0.00763
DA (day
21) Osteoclast apoptosis rate constant Could not be estimated, fixed at 1
b (%) Status of the disease
process at baseline
Could not be estimated, fixed at 1
Placebo-related parameters
kCa (day
21) Calcium elimination rate constant 0.00237 (14.43) NA NA
kCa,onset (day
21) Calcium elimination rate
constant for onset
NA 0.00128 (7.2) 0.0009 (12.4)
KCa,offset (day
21) Calcium elimination rate
constant for offset
NA 0.000374 (10.7) 0.000226 (21.9)
Transducer function bone turnover markers
BSAP0 (U/L) BSAP baseline value fixed at 97.4
a
kBSAP0 (2) BSAP baseline scaling parameter NA 20.894 (0.4) 20.896 (0.3)
NTX0 (nmol bce/mmol cr) NTX baseline value 35.9 (2.58) 53.4 (2.6) 49.5 (5.7)
qBSAP (2) BSAP transduction parameter fixed at 97.4
a
qNTX (2) NTX transduction parameter 0.366 (11.61) 0.564 (7.6) 0.56 (15.6)
Transducer function bone mineral density
kLS (mg/day) Zero-order turnover rate
constant for LS
0.11 (34.45) fixed at 0.11 NA
kin,ls (mg/day) Zero-order production rate
constant for LS-BMD
NA NA 1.13 (22.7)
LS-BMD0 (g/cm
2) LS-BMD baseline value 0.97 (0.8) 0.98 (0.8) 0.99 (0.7)
BMI-LS-BMD0 fraction (2) BMI fraction of LS-BMD baseline 0.00792 (14.90) 0.00892 (24.8) 0.0111 (14.5)
kTH (mg/day) Zero-order turnover rate
constant for TH
0.0821 (34.71) fixed at 0.0821 NA
kin,th (mg/day) Zero-order production rate
constant for TH-BMD
NA NA 0.295 (14.7)
TH-BMD0 (g/cm
2) TH-BMD baseline value 0.87 (0.8) 0.88 (0.8) 0.88 (0.7)
BMI-TH-BMD0 fraction (2) BMI fraction of TH-BMD baseline 0.0133 (8.95) 0.0118 (22.1) 0.0154 (11.4)
qBMD (2) BMD transduction parameter 0.784 (33.80) fixed at 0.784 NA
DAOB (2) Coefficients for stimulation by
relative osteoblast activity
NA NA 0.121 (6.0)
DAOC(2) Coefficients for stimulation by
relative osteoclast activity
NA NA 0.0456 (10.6)
Interindividual variability
IIV NTX0 (%) IVV NTX baseline 29 (7.1) 39 (5.2) 40 (3.5)
IIV BSAP0 (%) IVV BSAP baseline 25 (5.8) 33 (6.6) 32 (5.6)
IIV corr NTX0-BSAP0 (2) IVV correlation NTX-BSAP baseline 0.48 (10.0) 0.50 (15.7) 0.50 (12.1)
IIV BMDLS,0 (%) IVV LS-BMD baseline 11 (5.5) 12 (4.7) 12 (3.4)
IIV BMDTH,0 (%) IVV TH-BMD baseline 11 (5.7) 12 (4.5) 12 (3.4)
IIV corr BMDLS,0-TH,0 (2) IVV correlation LS-TH-BMD
baseline
0.62 (7.0) 0.59 (2.3) 0.60 (1.4)
Residual variability
eBSAP (SD) Residual variability BSAP 0.164 (2.1) 0.174 (4.4) 0.184 (4.6)
eBSAP,extremes (SD) Residual variability BSAP extremes 0.632 (13.6) 0.536 (22.9) 0.521 (22.8)
eNTX (SD) Residual variability NTX 0.312 (1.8) 0.307 (2.5) 0.314 (2.0)
eNTX, extremes (SD) Residual variability NTX extremes 0.984 (8.1) 0.570 (14.4) 0.511 (19.2)
eLS (SD) Residual variability LS-BMD 0.019 (2.2) 0.024 (3.6) 0.022 (2.7)
eTH (SD) Residual variability LS-BMD 0.015 (3.0) 0.021 (3.5) 0.020 (2.3)
NA: Not applicable.
aFixed at the tibolone value, see main text for explanation.
bCould not be estimated.
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dLSBMD
dt
¼ kinLS  11DAOB  yð Þ2koutLS  11DAOC  zð Þ  LS BMD
dTH BMD
dt
¼ kinTH  11DAOB  yð Þ2koutTH  11DAOB  zð Þ  TH BMD
(8)
where kinLS(TH) is a zeroth-order production rate con-
stant for LS-BMD (TH-BMD), koutLS(TH) is the first-order
degradation rate constant for LS-BMD (TH-BMD), and
DAOB and DAOC are the coefficients for stimulation by the
relative osteoblast (y) and osteoclast (z) activity. The
model, including the indirect response equations for
BMD, was then applied to EPIC 2. The resulting parame-
ters values are shown in Table 2. The two models
yielded similar values for baseline parameter values and
comparable values for the residual variability. Parameter
estimates for the indirect response equations for BMD
were consistent with physiological values reported in the
literature.23,24
To test the appropriateness of the current model, a visual
predictive check (VPC) and numerical predictive check
(NPC, see Supplementary Information) was performed.
In Figure 3 the relative changes from baseline are shown
on the study timescale for the degradation marker NTX,
bone formation marker BSAP, LS-BMD, and TH-BMD. The
results presented in Figure 3 show that the model
adequately describes all biomarker data as the 5th, 50th,
and 95th percentiles of the real data (red lines) overlap with
the 5th, 50th, and 95th percentiles of the simulated data
(black lines) and lay within the respective prediction inter-
vals (blue and red areas). Furthermore, the 5th, 50th, and
95th percentiles of the model prediction (black lines) follow
that of the real data (red lines). Overall, we conclude that
the model is able to describe the dynamics of the bio-
marker in the entire placebo arm to a very good
approximation.
Sensitivity of the system-specific parameters
As a second level of model qualification, we tested the sen-
sitivity of the system-specific parameters for both models
(EPIC 1 and EPIC 2). To find how these parameters vary,
the model was optimized with all other parameter values
fixed at the values as shown in Table 2, and each system-
specific parameter was estimated one at a time. Parame-
ters values for zs and kB were lower compared to the
tibolone study and could be estimated with acceptable pre-
cision. Kestrogen could not be identified for EPIC 1 and only
with a very high coefficient of variation for EPIC 2 (see
Table 3).
Simulations of BMD dynamics with zeroth-order and
indirect response model
Simulations with both types of BMD equations were per-
formed in order to compare the effect on the dynamics.
The parameter values as shown in Table 2 were used for
these simulations. For both equations the change of BMD
is determined by the balance between the relative changes
in y and z (i.e., S5 z/y). In Figure 4a it is shown how these
relative quantities evolve as a result of the placebo treat-
ment. Both models evolve towards a similar maximal value
of S. The underlying dynamics for both models is different,
however: the zeroth-order model has reached this maximal
value already after 2 years, whereas the indirect response
model reached this value only after 4 years. Note that S
represents the ratio of relative osteoclast activity over rela-
tive osteoblast activity. Therefore, there is net bone loss if
this ratio is bigger than 1 and net bone formation when it is
smaller than 1. This can also be seen in Figure 4b, where
the change of LS-BMD (gray lines) and TH-BMD (black
lines) over time is plotted and decreases as a result of dis-
ease progression. The difference in the two BMD equations
can be seen from this plot: the zeroth-order response func-
tion (solid lines) has a concave shape, whereas the indirect
response model (dashed lines) has a convex shape. This
implies that right after onset of disease progression (e.g.,
beginning of the menopause) the change in BMD is largest.
In addition, this change is bigger for LS-BMD compared to
TH-BMD. These model predictions were compared to the
available observations. So, for every individual we calcu-
lated the difference between baseline value and the latest
available measurement for LS- and TH-BMD and plotted
this difference vs. YSM. As shown in Figure 4c,d, we also
found the biggest change (i.e., decrease) in BMD at the LS
and TH shortly after onset of menopause, and the absolute
mean change was 25% higher in BMD at the lumbar
spine compared to the total hip.
DISCUSSION
In this study we applied a recently proposed disease sys-
tems analysis model for postmenopausal osteoporosis to
data from another population that was used for model
development and parameter fitting. The model is based on
a mechanistic model describing osteoblast and osteoclast
activity13 that has been reduced in order to apply it in a
population approach. It was shown that the model reduc-
tion did not jeopardize the dynamic properties of the
model.14 The reduced model was successfully applied to
describe responses in treatment with various doses of tibo-
lone and/or calcium in postmenopausal women.15 The cur-
rent systems pharmacology approach allowed us to test
whether the original values of the system-specific parame-
ters allowed for an adequate description of disease pro-
gression in a new (external) population. To this aim, we
used the placebo arm of the EPIC study.16 This led to a
total of 470 women who received placebo treatment for a
period of 4 years. Although others have looked at the mod-
eling of placebo response,25,26 to our knowledge this is the
first attempt to use a systems-pharmacology population
approach for the description of osteoporosis disease pro-
gression in response to placebo treatment in an external
population. Robust descriptions of the placebo response
and disease progression are crucial for the quantification
of treatment effects. The placebo effect, PCA (Eq. 3), was
updated with an onset and offset parameter and was incor-
porated into the model in a mechanism-based manner: as
an inhibitory factor of the RANK receptor occupancy as
calcium promotes its effects on the RANK- RANKL-OPG
system through PTH.13,15
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It should be noted that all subjects in the tibolone study
received 500 mg calcium carbonate once daily. In the EPIC
study, dietary calcium intake from food sources was monitored
using validated dietary questionnaires. Women with a calcium
intake of less than 500 mg per day were advised to increase
their intake (either by diet or supplements). In principle, all
women in the EPIC study should thus also have received at
least 500 mg calcium per day. Since this was monitored at
center visits only via questionnaires, more variation in calcium
intake could be expected for this study. In order to characterize
the true calcium effect, data obtained following the administra-
tion of different doses of calcium would be needed.
Figure 3 Visual predictive check plots of the degradation marker NTX, the bone formation marker BSAP, LS-BMD, and TH-BMD on
the study timescale for the model applied to all women in the placebo arm (EPIC 2). The blue dots represent the percentage change
from baseline of the available observations. The 5th, 50th, and 95th percentiles of the real data in the bins are presented by the red
dashed, red solid, and red dashed line, respectively. The 5th, 50th, and 95th percentiles of the simulated data (n5 500) in the bins are
presented by the black dashed, black solid, and black dashed line, respectively. The confidence interval for the simulated data 5th,
50th, and 95th percentiles for each of the bins is presented by the blue, red, and blue area, respectively. Note that BSAP was meas-
ured in a random sample of 205 women and not in the entire population.
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The disease systems analysis model is a mathematical
reduced version14 of the cell interaction model as proposed
by Lemaire et al.13 The model reduction did not influence the
model dynamics and bears the advantage that all remaining
parameter values are identifiable despite the fact that the bio-
markers available in this study respond at different timescales
upon treatment with placebo. With all system-specific param-
eter values fixed at their published values, we showed that
the model is able to adequately describe the dynamics of the
biomarkers within the external population. Furthermore, a
sensitivity analysis revealed that, with the exception of
kestrogen, all systemic parameters could be reestimated with
the current data and their values were in the same range as
the previously reported values. Possibly, the heterogeneity in
YSM in the population resulted in the large uncertainty of the
kestrogen parameter. We anticipate that on the basis of individ-
ual serum estrogen levels a better description of the underly-
ing disease dynamics will be feasible.
Table 3 Change in single system-specific parameter values when the disease systems analysis model was optimized with all other parameters fixed according
to the values as shown in Table 2
Parameter
(unit)
Value (%CV)
tibolone study
Value (%CV)
EPIC 1 1£YSM£5
Fold change
difference
Value (%CV)
EPIC 2 All YSM
Fold change
difference
zs (2) 0.659 (24.0) 0.497 (27.6) 0.75 0.366 (19.9) 0.55
kB (day
21) 0.0109 (11.9) 0.0032 (36.5) 0.29 0.0019 (22.4) 0.17
kestrogen (day
21) 0.0076 (21.3) (2)** NA 0.018 (201) 2.4
Da (day21) 1*(2) 1*(2) NA 1*(2) NA
b (%) 1*(2) 1*(2) NA 1*(2) NA
*Fixed at 1.
**Could not be estimated.
NA, not applicable.
Figure 4 Comparison of zeroth-order and indirect response model for BMD dynamics. (a) Changes in the net bone cell activity (S5 z/y)
vs. time for the zeroth-order process (ZO, solid line) and the indirect response model (IR, dashed line). The arrows indicate the start and
end of the placebo treatment in the two studies. (b). Changes in LS-BMD (gray lines) and TH-BMD (black lines) for the zeroth-order pro-
cess (solid line) and the indirect response model (dashed line). Scatterplot showing the change between baseline and the latest observa-
tion available for LS-BMD (c) and TH-BMD (d) vs. years since menopause.
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The most notable difference between the two clinical
studies is the YSM at baseline. In the model the YSM are
incorporated as the timescale of disease progression (Fig-
ure 2). Inclusion of the entire range of YSM in our analysis
required the adaptation of the equation for the BMD
dynamics. The indirect response model23 used in this study
can be seen as a more extensive form of the (originally pro-
posed) zeroth-order process. With this small adaptation we
were able to describe the dynamics in all biomarkers for
the entire range of YSM with good precision. Furthermore,
the fact that the model also accurately describes disease
progression far outside the timeframe compared to the
timeframe that was used originally in the tibolone study pro-
vides evidence for the values of the system-specific param-
eters. These results provide a strong basis for the potential
to use this disease systems analysis model to evaluate the
(comparative) effect of other drugs with different mecha-
nisms (e.g., bisphosphonates, unpublished data), or link the
mechanism-based core of this model to different
biomarkers.
The core model is defined to describe the dynamics as a
relative change related to the information in the dynamics
of the markers linked to it (based on their relationship to
the system). We believe, and this should be tested, that all
types of markers can be linked and inform such a system.
Whether that holds remains to be seen based on available
data. In contrast to the tibolone study, we did not have
measurements on the biomarker osteocalcin available.
Osteocalcin is a biomarker for the combined osteoblast and
osteoclast activity. Osteocalcin is built into bone—when
bone is degraded it will become available again in the sys-
temic circulation so the measurement is a composite of
building and degradation of bone. We found that removal of
osteocalcin from the model did not alter its performance.
This also shows the strength of a disease systems analysis
model; the core remains the same and the markers supply-
ing the required information on the system can change,
which is in contrast to empirical models where (single)
marker(s) are directly linked. On the other hand, it remains
to be seen how this removal will affect future applications
of the model when other drug treatments are considered.
In conclusion, we have shown that a recently proposed
disease systems analysis model for osteoporosis can be
applied to describe the effect of the placebo treatment on
disease progression in a new population. The mechanism-
based model allowed for 1) an adequate description of the
available biomarkers, 2) allowed for the inclusion of the
years since menopause (the characteristic timescale in the
model) that was more than five times longer than in the
original model. These findings can be considered a first
step towards model validation and qualification of this
osteoporosis model, which will be further elaborated by
also applying the model to other therapeutic interventions.
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